Retatrutide is generating considerable interest as a potential breakthrough in obesity treatment, but does retatrutide work for everyone? As an investigational triple-receptor agonist targeting GLP-1, GIP, and glucagon pathways simultaneously, it has demonstrated impressive results in early clinical trials. However, individual responses vary meaningfully depending on biology, lifestyle, and tolerability. This article examines how retatrutide works, what the clinical evidence shows about who responds and who does not, and what UK patients should know about its current availability and suitability.

How Retatrutide Works in the Body

Retatrutide simultaneously activates GLP-1, GIP, and glucagon receptors, combining appetite suppression, enhanced insulin sensitivity, and increased energy expenditure in a single triple-agonist mechanism.

Retatrutide is an investigational medication that belongs to a class of drugs known as multi-incretin receptor agonists. Unlike earlier weight-management treatments that target a single hormone receptor, retatrutide simultaneously activates three distinct receptors: the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor. This triple-agonist mechanism distinguishes it from agents such as semaglutide (a GLP-1 receptor agonist) or tirzepatide (a dual GIP/GLP-1 receptor agonist).

By activating the GLP-1 receptor, retatrutide is thought to promote insulin secretion in a glucose-dependent manner, slow gastric emptying, and reduce appetite — effects well-established with existing GLP-1-based therapies. The additional activation of the GIP receptor is hypothesised to enhance insulin sensitivity and may contribute to improved tolerability of the GLP-1 component, though this remains under investigation and has not been definitively demonstrated for retatrutide specifically; much of this reasoning is extrapolated from tirzepatide data. The glucagon receptor component is believed to increase energy expenditure and promote hepatic fatty acid oxidation and ketogenesis, which may help address metabolic dysfunction associated with obesity. It is important to note that some of these mechanistic effects are supported primarily by preclinical or early human data, and further research is needed to confirm their relative contributions in people.

Despite the glucagon receptor agonism — which might theoretically raise blood glucose — net glycaemic effects in the Phase 2 obesity trial (conducted in adults without diabetes) were favourable, likely because the GLP-1 and GIP components counterbalance glucagon's glucose-raising effects. It is also worth noting that multi-receptor agonism may carry trade-offs, including a small increase in heart rate observed in clinical trials, consistent with the incretin drug class.

Together, these three mechanisms create a complementary effect on energy intake, energy expenditure, and metabolic regulation. This multi-pronged approach is the scientific rationale for why retatrutide has demonstrated substantial weight loss in early clinical trials. However, because the drug acts on several biological pathways simultaneously, individual responses can vary considerably depending on a person's underlying physiology, hormonal environment, and metabolic health.

Clinical Trial Results: Who Responded and Who Did Not

In a 2023 Phase 2 trial, the highest dose produced a mean body weight reduction of approximately 24%, but some participants lost less than 5% of body weight, confirming that response is not universal.

The most significant clinical data for retatrutide to date comes from a Phase 2 trial published in the New England Journal of Medicine in 2023. In this randomised, double-blind, placebo-controlled study, adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one weight-related comorbidity received weekly subcutaneous injections of retatrutide at varying doses over 48 weeks. Importantly, the trial enrolled participants without diabetes; findings may therefore not be directly generalisable to people with type 2 diabetes, for whom separate data are needed. The results were notable: participants receiving the highest dose (12 mg) achieved a mean body weight reduction of approximately 24%, which is among the largest reductions observed in any pharmacological weight-loss trial to date. Many participants had not yet reached a weight-loss plateau at 48 weeks, suggesting that longer-term reductions may be greater still.

However, not all participants responded equally. Whilst the majority of those in the active treatment groups experienced clinically meaningful weight loss, a proportion achieved more modest results. Across all dose groups, there was a clear dose–response relationship, with higher doses generally producing greater weight loss — though this also correlated with a higher incidence of gastrointestinal side effects such as nausea, vomiting, and diarrhoea.

Key observations from the trial data include:

• Responder rates were high but not universal — some individuals lost less than 5% of body weight even at therapeutic doses. In the highest-dose group, the proportions achieving ≥5%, ≥10%, and ≥15% weight loss were substantially greater than with placebo, though precise figures should be verified against the published trial report.

• Tolerability was a limiting factor for some participants, with dose reductions or discontinuations occurring due to adverse effects.

• Other safety signals consistent with the incretin drug class were observed, including a small increase in resting heart rate and gallbladder-related events (such as cholelithiasis), which are associated with rapid weight loss and are reported with other agents in this class.

• Any apparent influence of baseline characteristics (such as starting BMI or metabolic profile) on outcomes should be considered exploratory, as the trial was not powered to formally test these subgroup effects.

These findings confirm that whilst retatrutide shows exceptional promise, it does not work uniformly for everyone, and individual variability in response is a clinically relevant consideration.

Factors That May Affect How Well Retatrutide Works

Efficacy may be influenced by hormonal profile, insulin resistance, genetic variation, gut microbiome composition, adherence to dosing, and concurrent lifestyle changes, though many of these factors remain speculative for retatrutide specifically.

Several biological, behavioural, and pharmacological factors may influence how effectively retatrutide works in any given individual. Understanding these variables is important for setting realistic expectations and for tailoring treatment approaches.

Biological and metabolic factors (largely theoretical for retatrutide):

• Hormonal profile: It is hypothesised that individuals with differing baseline levels of GLP-1, GIP, and glucagon may respond differently to receptor stimulation, but this has not been formally demonstrated for retatrutide and should be regarded as speculative.

• Insulin resistance: The degree of insulin resistance may affect how the body responds to the GIP and GLP-1 components of the drug, though again this is extrapolated from class data rather than retatrutide-specific evidence.

• Genetic variation: Polymorphisms in incretin receptor genes may theoretically influence receptor sensitivity and drug efficacy, but this remains an area of early-stage research with no established clinical application for retatrutide.

• Gut microbiome: Emerging evidence suggests that gut microbiome composition may modulate responses to incretin-based therapies; however, this has not been specifically studied with retatrutide and should be considered highly preliminary.

Lifestyle and adherence factors:

• Retatrutide is not a standalone treatment. Clinical trials were conducted alongside dietary and lifestyle counselling, consistent with NICE guidance on obesity management. Individuals who do not make concurrent changes to diet and physical activity are likely to see diminished results.

• Adherence to the dosing schedule is critical. Missing doses or failing to titrate appropriately may reduce efficacy.

Pharmacological considerations:

• Retatrutide slows gastric emptying, which may alter the absorption of some oral medicines — including oral contraceptives. Prescribers should review concomitant medications before initiating treatment, as is recommended for other incretin-based therapies (see, for example, the EMC SmPCs for semaglutide/Wegovy® and tirzepatide/Mounjaro®).

• If retatrutide were used alongside insulin or sulfonylureas, the risk of hypoglycaemia may increase; doses of these agents may need to be reviewed by a clinician.

• Tolerability issues leading to dose reductions may limit the therapeutic benefit achievable in some patients.

These factors collectively highlight that retatrutide's effectiveness is not solely determined by the drug itself, but by the complex interplay between the individual's biology and their broader health behaviours.

Who May Not Be Suitable for Retatrutide

Those with a history of pancreatitis, gastroparesis, pregnancy, type 1 diabetes, or significant gallbladder disease may not be suitable, based on incretin-class pharmacology and available trial data.

As retatrutide remains an investigational drug and has not yet received marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency (EMA), a formal list of contraindications has not been established in the same way as for licensed medicines. Nevertheless, based on available clinical trial data and the known pharmacology of incretin-based therapies, certain groups may require particular caution.

Groups for whom retatrutide may not be appropriate include:

• Those with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2): Rodent studies with GLP-1 receptor agonists have shown thyroid C-cell tumours; however, a causal link in humans has not been established, and this is not a formal contraindication in UK SmPCs for licensed GLP-1 receptor agonists such as semaglutide or tirzepatide. Individuals with a relevant personal or family history should discuss this with their clinician, who can assess the risk in context.

• Individuals with a history of pancreatitis: Incretin-based therapies have been associated with reports of pancreatitis, though causality remains uncertain. UK SmPCs for licensed agents advise caution and prompt assessment if severe abdominal pain with or without vomiting develops. The same precaution is prudent for retatrutide.

• Pregnant or breastfeeding women: There are no adequate safety data in pregnancy for retatrutide. Weight-loss treatment is generally not recommended during pregnancy. For licensed GLP-1 receptor agonists, UK SmPCs advise against use in pregnancy and breastfeeding, and recommend that women use effective contraception during treatment and for a defined washout period afterwards. Similar principles are likely to apply to retatrutide, though specific guidance has not yet been established.

• Those with severe gastrointestinal conditions, including gastroparesis: Given the drug's effects on gastric motility, individuals with gastroparesis or other severe upper gastrointestinal disorders may experience worsening symptoms.

• People with type 1 diabetes: The glucose-dependent insulin-secretion mechanism is less relevant in the absence of functional beta cells, and the risk–benefit profile in this group is unclear.

• Those at risk of dehydration or acute kidney injury: Persistent vomiting or diarrhoea — which can occur with incretin-based therapies — may lead to dehydration and, in some cases, acute kidney injury. Individuals with pre-existing renal impairment or other risk factors should be monitored carefully.

• Those at risk of gallbladder disease: Rapid weight loss is associated with an increased risk of cholelithiasis (gallstones). This has been observed with other agents in the incretin class and is a relevant consideration for retatrutide.

It is also worth noting that individuals who did not respond to or could not tolerate other GLP-1-based therapies may have a reduced likelihood of benefiting from retatrutide, though this has not been formally studied. A thorough medical assessment would be essential before initiating treatment.

What to Do If Retatrutide Is Not Working for You

Allow at least 12–16 weeks at the target dose before assessing response, review lifestyle factors, discuss dose optimisation with your prescriber, and seek medical advice if you have lost less than 5% body weight by week 16.

If you are participating in a clinical trial or accessing retatrutide through another route and feel that the treatment is not producing the expected results, there are several important steps to consider before drawing conclusions or making changes independently.

First, allow adequate time. Weight loss with incretin-based therapies is typically gradual. Meaningful results may not be apparent until 12–16 weeks into treatment, particularly during the dose-escalation phase. Premature discontinuation is a common reason for suboptimal outcomes.

Review lifestyle factors. Retatrutide is intended to complement — not replace — dietary modification and increased physical activity, in line with NICE guidance on obesity management. If these elements are not in place, the drug's efficacy will likely be reduced. Speaking with a dietitian or a specialist weight management service can be beneficial.

Discuss dose optimisation with your prescriber. If you are on a lower dose due to tolerability concerns, your clinician may be able to adjust the titration schedule to allow your body more time to adapt, potentially enabling a higher therapeutic dose over time.

Consider when to seek medical advice:

• If you have lost less than 5% of your body weight after approximately 16 weeks at the target dose, discuss this with your supervising clinician. Note that this threshold is a general principle extrapolated from criteria used for licensed anti-obesity medicines (such as those in NICE TA875 for semaglutide and the 2024 NICE technology appraisal for tirzepatide); it has not been formally validated for retatrutide.

• If you are experiencing persistent side effects that are affecting your quality of life or adherence, do not stop the medication abruptly — contact your GP or trial coordinator.

• If you develop symptoms such as severe abdominal pain, persistent vomiting, or signs of an allergic reaction, seek urgent medical attention. In the UK, call NHS 111 for urgent advice, or 999 and go to A&E if symptoms are severe or life-threatening.

• If you experience signs of dehydration (such as dizziness, reduced urine output, or confusion) due to prolonged vomiting or diarrhoea, seek prompt medical attention, as this can affect kidney function.

Report suspected side effects. If you experience a suspected adverse reaction to retatrutide, you can report it via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk or through the Yellow Card app. This applies even within a clinical trial setting and helps build the safety evidence base for investigational medicines.

For those who do not respond adequately, alternative pharmacological options — such as licensed GLP-1 receptor agonists or referral to a specialist obesity service — should be explored in line with NICE guidance.

Current Availability and Guidance in the UK

Retatrutide is not licensed by the MHRA and is unavailable outside clinical trials in the UK; current NICE-recommended obesity treatments include orlistat, semaglutide (Wegovy®), and tirzepatide (Mounjaro®).

As of the time of writing, retatrutide is not licensed for use in the United Kingdom. It has not received marketing authorisation from the MHRA, and it is not currently recommended by NICE for the treatment of obesity or any other condition. Its use in the UK is therefore effectively restricted to clinical trial settings. Unlike some other investigational medicines, retatrutide does not currently have a listing under the MHRA's Early Access to Medicines Scheme (EAMS), which is the primary UK route for pre-authorisation access outside of trials. Routine access via named-patient or compassionate use programmes is not a standard pathway in the UK and would require specific regulatory justification; patients should not assume such access is available.

The drug is being developed by Eli Lilly and Company, and Phase 3 clinical trials are ongoing. These larger trials will provide more robust data on long-term efficacy, safety, and the characteristics of those most likely to respond — information that will be essential for any future regulatory submission to the MHRA or EMA.

For individuals in the UK seeking treatment for obesity or overweight, current NICE-recommended options include:

• Lifestyle interventions as the first-line approach, including dietary counselling and increased physical activity.

• Licensed pharmacotherapy, such as orlistat (available on NHS prescription) or, more recently, semaglutide (Wegovy®), which has received NICE approval for specific indications (NICE TA875), and tirzepatide (Mounjaro®), which has received NICE approval for weight management (2024 NICE technology appraisal).

• Referral to specialist weight management services for those with complex needs or significant comorbidities.

Patients should be cautious about accessing retatrutide through unregulated online sources or private clinics offering unlicensed treatments, as the safety and quality of such products cannot be guaranteed.

Anyone interested in participating in a clinical trial involving retatrutide can search NIHR Be Part of Research (bepartofresearch.nihr.ac.uk) or ClinicalTrials.gov (searching for retatrutide or LY3437943) for currently recruiting studies. The EU Clinical Trials Register may not reflect UK trial availability following the UK's departure from the EU. Always consult your GP before making any changes to your weight management plan.

Frequently Asked Questions